Epcoritamab
- Generic Name
- Epcoritamab
- Brand Names
- Epkinly, Tepkinly
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2134641-34-0
- Unique Ingredient Identifier
- D6OMY2L0WA
- Background
Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells. Epcoritamab promotes the activation and expansion of T-cells and, by being able to bind to both CD20 and CD3, it leads to the T-cell–mediated killing of CD20+ malignant B cells. Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of cancer comm...
- Indication
Epcoritamab is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under acc...
- Associated Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Associated Therapies
- -
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL
- Conditions
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 102
- Registration Number
- NCT04542824
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima-shi, Japan
🇯🇵National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Japan
🇯🇵National Cancer Center Hospital, Chuo Ku, Japan
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Genmab
- Target Recruit Count
- 46
- Registration Number
- NCT04358458
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 666
- Registration Number
- NCT03625037
- Locations
- 🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇺🇸University of California at San Francisco, San Francisco, California, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.